Mood, hormones and quality of life

Clinica Terapeutica

Volumn 159, Issue 2, 2008, Pages 105-109

  Mazza, Marianna ^a,b   Bria, P ^a   Taranto, C ^a   Janiri, L ^a   Mazza, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NONE   (Italy)

Author keywords

Hormones; Mood; Neuroendocrine system; Quality of life

Indexed keywords

ESTROGEN; GROWTH HORMONE; HORMONE; TESTOSTERONE; THYROXINE;

ACUTE DISEASE; CAREGIVER; CLINICAL STUDY; CONVALESCENCE; DISTRESS SYNDROME; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; ESTROGEN THERAPY; FAMILY; HEALTH BEHAVIOR; HORMONE SUBSTITUTION; HUMAN; ILLNESS BEHAVIOR; LOADING DRUG DOSE; MOOD DISORDER; QUALITY OF LIFE; REVIEW;

AFFECT; AGED; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HORMONES; HUMAN GROWTH HORMONE; HUMANS; HYPERTHYROIDISM; LIFE CHANGE EVENTS; MALE; POSTMENOPAUSE; PSYCHOTROPIC DRUGS; QUALITY OF LIFE; TESTOSTERONE; THYROXINE;

EID: 43549083684     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Ritsner M, Modai I, Endicott J, et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 2000; 61(11):880-9
2. Ritsner M, Kurs R. Quality of life outcomes in mental illness: schizophrenia, mood and anxiety disorders. Expert Rev Pharmacoeconomics Outcomes Res 2003; 3(2):89-99
3. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hops Com Psychiatry 1992; 43:262-5
4. Ritsner M, Kurs R, Gibel A, et al. Predictors of quality of life in major psychoses: a naturalistic follow-up study. J Clin Psychiatry 2003; 64(3):308-15
5. Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis 2003; 191:287-94
6. Ritsner M, Ben-Avi I, Ponizovsky A, et al. Quality of life and coping with schizophrenic symptoms. Quality of Life Res 2003; 12:1-9
7. Ritsner M, Gibel A, Ratner Y. Determinants of changes in perceived quality of life in the course of schizophrenia. Quality of Life Res 2006; 16:515-26
8. Mazza M, Mazza S. Neuroendocrine functions, mood and quality of life. In: MS Ritsner and AG Award (Editors). Quality of Life Impairment Syndrome in Schizophrenia, Mood and Anxiety Disorders: A new Concept for Research, Treatment, and Rehabilitation. Springer, The Netherlands, 2007; 33-56
9. Mazza M, Satta MA, Bria P, et al. Neuroendocrinology of mood disorders. Clin Ter 2004; 155(11-12):537-41
10. Ozkan S, Alatas E, Zencir M. Women's quality of life in the premenopausal and post menopausal periods. Qual Life Res 2005; 14:1795-1801
11. Almeida OP, Lautenschlager NT, Vasikaran S, et al. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol Aging 2006; 27:141-9
12. Manson JE, Bassuk SS, Harman SM, et al. Postmenopausal hormone therapy : new questions and the case for new clinical trials. Menopause 2006; 13(1):139-47
13. Halbreich U, Borenstein J, Pearlstein T, et al. The prevalence, impairment, impact and burden of premenstrual dysphoric disorder. Psychoneuroendocrinol 2003; 28:1-23
14. Arwert LI, Deijen JB, Muller M, et al. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Hormones Behav 2005; 47:343-9
15. Stouthart PJHM, Deijen JB, Roffel M, et al. Quality of life of growth hormone deficient young adults during discontinuation and restart of GH therapy. Psychoneuroendocrinol 2003; 28:612-26
16. Haren MT, Wittert GA, Chapman IM, et al. Effect of oral testosterone undecanoate on visuospatial cognition, mood and quality of life in elderly men with low-normal gonadal status. Maturitas 2005; 50:124-33
17. Delhez M, Hansenne M, Legros JJ. Andropause and psychopathology: minor symptoms rather than pathological ones. Psychoneuroendocrinol 2003; 28:863-74
18. Finas D, Bals-Pratsch M, Sandmann J, et al. Quality of life in elderly men with androgen deficiency. Andrologia 2006; 38(2):48-53
19. Nair KS, Rizza RA, O'Brien P et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355(16):1647-59
20. Strous RD, Stryjer R, Maayan R, et al. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following DHEA administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Psychoneuroendocrinilogy 2007; 32(2):96-105
21. Fahrenfort JJ, Wilterdink AML, van der Veen EA. Long-term residual complaints and psychosocial sequelae after remission of hyperthyrioidism. Psychoneuroendocrinol 2000; 25:201-11
22. Coker LH, Kashemi R, Cantley L, et al. Primary hyperparathyroidism, cognition, and health-related quality of life. Annals of Surgery 2005; 242(5):642-50
23. Walsh JP, Ward LC, Burke V, et al. Small changes in thyroxine dosage do not produce measurable changes in hypothyroid symptoms, well-being, or quality of life: results of a double-blind, randomized clinical trial. J Clin Endocrinol Metab 2006; 91(7):2624-30
24. Bianchi GP, Zaccheroni V, Solaroli E, et al. Health-related quality of life in patients with thyroid disorders. Qual Life Res 2004; 13(1):45-54
25. Robb JC, Cooke RG, Devins GM, et al. Quality of life and lifestyle disruption in euthymic bipolar disorder. J Psychiatr Res 1997; 31(5):509-17
26. Vojta C, Kinosian B, Glick H, et al. Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry 2001; 42(3):190-5
27. Kasper SF. Living with bipolar disorder. Expert Rev Neurotherapeutics 2004; 4(6 Suppl 2): 9-15